Archive for the ‘Dermatology News’ Category
The best dermatologist on Long Island is important for people who need some help feeling comfortable in their own skin. From acne to irregular moles, a dermatologist is there to make sure everything on is smooth on the surface. We bring you this years winners for Best Dermatologist on Long Island.
Long Islanders Voted Dr. Jeffrey Ellis from Belaray Dermatology in Plainview Best Dermatologist on Long Island!
Belaray means beautiful, and that’s how Jeffrey Ellis’ patients feel when they walk out of his office. Dr. Ellis’ goal is to provide comprehensive compassionate care for adults and children in a timely manner. Belaray provides specialized skin care for patients of all ages, from general dermatology, like acne treatment, to surgical dermatology, like scar revisions and even medi-spa esthetic services.
To the gardening world it may have always been considered a fact, but science has never proved the widely held belief that watering your garden in the midday sun can lead to burnt plants. Now a study into sunlit water droplets, published in New Phytologist, provides an answer that not only reverberates across gardens and allotments, but may have implications for human sunburn.
Wine May Shield Breast Cancer Patients From Radiation Side Effects
Italian study suggests its natural antioxidants protect the skin
A glass of wine a day cut the risk of treatment-linked skin toxicity by two-thirds in women undergoing radiation therapy for breast cancer, Italian researchers report.
Skin reactions are a common side effect of cancer radiation therapy, and, while medications can help prevent these problems, they can be expensive and often have their own side effects. In some cases, drugs used to reduce radiation-linked side effects can actually protect breast cancer tumor cells, according to a news release from the American Society for Radiation Oncology.
Izzie, from Grey’s Anatomy, was diagnosed with stage 4 melanoma in season five.
Melanoma is the most serious type of skin cancer, that is most common in fair skinned individuals. In sun prone areas, like New Zealand, about one in fifteen Caucasians will be diagnosed with one. Most melanoma is diagnosed after age 40, with only about 14% of cases diagnosed in younger individuals. In the US, about 55,000 cases are diagnosed per year, and on average one person dies every hour from this cancer.
Melanoma, when diagnosed early, is almost always treatable. When diagnosed late, the prognosis is often poor, and effective treatment options limited.
What should you do?
1. Protect yourself from the sun using hats, seeking shade, and avoiding peak hours of the day (from 10am-4pm)
2. Learn what the signs of a problem are – when you examine your moles and freckles
2. Make an appointment with your dermatologist for a full body skin examination – and bring your family
Here is information about clinical trials in NY for treating Melanoma
Smile at the world… and the world will smile back.
According to a study published the March issue of the Journal of Cosmetic Dermatology, Botox may lift patients’ “spirits” by “literally wiping the frowns” off their faces. It has been long known that our facial expressions can influence our mood – and simply smiling can make you feel better. Not surprisingly, it seems that Botox can have the same beneficial effects.
Research suggests that Caffeine kills some skin cancer cells. According to a study published in the Journal of Investigative Dermatology this month, “caffeine could be added to sunscreen to boost protection against the most common form of skin cancer.” We do not find this surprising. Infact, we have thought that for a long time. That is why we offer our patients a sunscreen that has Caffeine as well as potent antioxidants from green tea. We believe that the best protection you can get is by combining sunscreen, caffeine, and anteoxidants – and that is just what we do in our Anteox Sunscreen.
BBC News reports, “An unlicensed medicine which can be injected to produce a tan may be responsible for worrying changes in skin moles, say doctors. Two women told Salford dermatologists that they had both injected ‘Melanotan’ shortly before noticing the problem.” One woman “had two moles on her foot which had increased in size and darkened over just a few weeks. The other, who was 30, told doctors that the moles on her back had also rapidly darkened.” Medical watchdog groups “have issued warnings about the untested nature of the Internet-supplied jabs, the British Medical Journal reports.
We do not recommend to our patients the use of this product.
Scientists have discovered the earlier the vaccine is used, the better. Skin cancer can
take years to develop and the jab works best if given before cells begin to mutate within the skin.
It raises the possibility that the vaccine, which has a better safety record than many
others, could be used in childhood to protect against the disease later in life, providing
further studies support the latest findings.
Malignant melanoma kills around 1,700 people a year and is the third most common
cancer in people aged 15 to 39. Over-exposure to the sun’s rays is the biggest cause and since the mid-1990s there has been a 24 per cent increase in cases in the UK.
Bloomberg News (11/16, Scott) reported that a “vaccine to prevent skin cancer may be ready for children within five to 10 years.” In fact, the “Australian scientist who created vaccinations for cervical cancer” has tested such a vaccine on animals.
According to Gardasil developer Prof. Ian Frazer, “it was not yet known how many skin cancers were caused by the” human papillomavirus, “a common infection which can turn abnormal cells into cancer,” AFP (11/16) added. Yet, the “new vaccine would target” human papillomavirus, and it “would be used on children aged between 10 and 12 to prevent them from developing skin cancer,” according to Frazer, who is expected to deliver “his findings to the Australian Health and Medical Research Congress on Monday.”
Experimental Drug Ustekinumab Trumps Enbrel in 3-Month Trial; Longer-Term Results Unknown
An experimental drug called ustekinumab shows better treatment results than an established drug, Enbrel, for treating moderate to severe plaque psoriasis in a new trial.
In a news release, the drug company Centocor, which makes ustekinumab and sponsored the study, calls the new drug “superior” to Enbrel.
But Amgen, the drug company that makes Enbrel, notes that the study only lasted for 12 weeks and didn’t address long-term safety.
Both ustekinumab and Enbrel are biologic drugs. Ustekinumab targets two inflammatory chemicals, interleukin 12 and interleukin 23. Enbrel is a TNF blocker; that is, it inhibits tumor necrosis factor (TNF).
In the new study, 903 patients with moderate to severe plaque psoriasis either got ustekinumab (in a higher or lower dose) or Enbrel for 12 weeks.
Patients in the ustekinumab groups got one shot of the experimental drug in their assigned dose when the study started and another shot four weeks later. Patients in the Enbrel group got two shots of Enbrel every week for 12 weeks.